China is a major producer of bulk drugs and a major consumer of drugs in the world. However, at present, the chemical drugs produced in China lack independent intellectual property rights, of which 97% are generic drugs, which are at a disadvantage in international competition. In this regard, relevant experts put forward suggestions on the future R&D direction and product structure adjustment of Chinese pharmaceutical enterprises.

In the near future, some patients with hypertension may be able to effectively control their blood pressure simply by injecting vaccines. The therapeutic vaccine is the result of years of research and development by a Swiss pharmaceutical company. At present, the vaccine is still in a small-scale clinical trial. 48 hypertensive patients have completed an injection course, and the expected antihypertensive effect can last about 4 months. It is reported that the vaccine will be launched within five years, and relevant research results have been published in the famous British medical journal The Lancet.

On August 18, more than 50 drugstore chiefs from 11 cities in Zhejiang Province gathered in Hangzhou to officially establish the "Zhejiang Pharmaceutical Retail (Chain) Enterprise Joint Procurement Center", and decided to collectively invite bids from pharmaceutical manufacturers to reduce costs and seek new development space. This is the first non-profit drug joint procurement center in Zhejiang Province and even in China. According to insiders, this indicates that the pharmacy industry has shifted from passive price reduction to "active attack".